Get started

Financials · CODX

Co-Diagnostics Inc. (CODX) financials

For the twelve months ended Jun 30, 2026, Co-Diagnostics Inc. reported $721.4K of revenue and -$47.06M of net income.

Revenue, TTM
$721.4K
Revenue growth, YoY
-28.1%
Net income, TTM
-$47.06M
Net margin
-6523.0%
Free cash flow, TTM
-$27.47M
Cash
$3.65M
P/S
3.21
Market cap
$2.3M
Annual revenue$622.5K
FY2017FY2025
Annual net income-$46.90M
FY2016FY2025
Annual free cash flow-$29.84M
FY2016FY2025

CODX revenue and earnings growth

CODX revenueQ2 2026$166.1K

Quarter YoY
+2.0%
QoQ
+13.8%
FY YoY
-84.1%
5Y CAGR
-61.6%

CODX revenue was $166.1K in fiscal Q2 2026 (ended Jun 30, 2026), up 2.0% from a year earlier and up 13.8% from the prior quarter. For the full fiscal 2025 it was $622.5K, down 84.1% from fiscal 2024. Compound annual growth was -61.6% over 5 years. It rose in 4 of the last 8 fiscal years.

CODX net incomeQ2 2026-$6.28M

CODX net income was -$6.28M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$7.73M a year earlier. For the full fiscal 2025 it was -$46.90M, compared with -$37.64M in fiscal 2024.

CODX EPSQ2 2026-$1.46

CODX diluted EPS was -$1.46 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$35.25, compared with -$37.22 in fiscal 2024.

CODX free cash flowQ2 2026-$7.17M

CODX free cash flow was -$7.17M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$8.69M a year earlier. For the full fiscal 2025 it was -$29.84M, compared with -$29.90M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$622.5K$3.92M$6.81M$34.22M$97.89M$74.55M$215.0K$39.9K$7.7K-
Cost of revenue$222.4K$999.1K$4.18M$5.48M$11.57M$16.59M$112.4K$9.4K$302-
Gross profit$400.1K$2.92M$2.63M$28.74M$86.31M$57.96M$102.5K$30.5K$7.4K-
Research and development$19.14M$20.98M$22.96M$17.44M$14.96M$3.19M$1.37M$1.36M$1.00M$731.5K
Selling, general and admin$9.06M$16.16M$14.28M$14.26M$11.55M$8.28M$3.50M$3.57M$3.10M$796.9K
Operating income-$50.17M-$40.08M-$42.71M-$26.98M$46.06M$41.69M-$5.89M-$6.12M-$4.56M-$1.69M
Interest expense------$106.4K-$310.2K$240.7K
Pre-tax income-$48.51M-$37.58M-$38.11M-$18.85M$45.64M$42.57M-$6.20M-$6.27M-$6.96M-$1.93M
Income tax-$1.62M$57.4K-$2.78M-$4.61M$8.98M$90.5K----
Net income-$46.90M-$37.64M-$35.33M-$14.24M$36.66M$42.48M-$6.20M-$6.27M-$6.96M-$1.93M
EPS, basic-$35.25-$37.22-$36.00-$13.50$38.10$47.70-$11.10-$15.00-$18.90-
EPS, diluted-$35.25-$37.22-$36.00-$13.50$36.90$45.60-$11.10-$15.00-$18.90-
Diluted shares1.3M1.0M978,219.9671.0M996,789.533933,344.7558,563.733416,153.9365,344.2329,413.167

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$11.88M$2.94M$14.92M$22.97M$88.61M$42.98M$893.1K$950.2K$3.53M$998.7K
Short-term investments-$26.81M$43.63M$58.29M$1.26M$4.34M----
Receivables$190.4K$132.6K$303.9K$3.45M$20.84M$12.14M$131.4K$13.4K--
Inventory$992.4K$1.07M$1.66M$5.31M$2.00M$8.00M$197.2K$18.2K$9.1K-
Current assets$13.69M$32.29M$62.14M$92.73M$115.12M$67.81M$1.58M$1.05M$4.45M$1.21M
Goodwill----$14.71M-----
Total assets$24.74M$63.56M$95.32M$123.09M$160.03M$71.24M$2.22M$1.55M$4.66M$1.30M
Current liabilities$3.54M$7.32M$5.75M$3.87M$12.60M$4.06M$328.1K$2.35M$628.3K$3.85M
Short-term debt-------$1.91M-$2.56M
Long-term debt-------$1.91M$277.7K-
Total debt-------$3.82M$277.7K-
Total liabilities$4.11M$9.69M$9.31M$8.57M$25.56M$4.54M$478.1K$2.61M$811.8K$4.29M
Shareholders' equity$20.63M$53.88M$85.58M$114.52M$134.48M$66.70M$1.74M-$1.06M$3.85M-$2.99M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$29.14M-$29.16M-$22.08M$6.57M$41.08M$28.17M-$5.53M-$4.08M-$3.21M-$1.31M
Capital expenditures$700.0K$748.4K$1.37M$1.43M$669.5K$774.4K$113.2K$41.3K$129.3K$12.2K
Free cash flow-$29.84M-$29.90M-$23.45M$5.14M$40.41M$27.39M-$5.64M-$4.12M-$3.34M-$1.32M
Investing cash flow$26.27M$17.07M$15.39M-$58.17M$4.10M-$5.82M-$435.2K-$380.3K-$189.3K-$12.2K
Financing cash flow$11.81M$103.9K-$1.36M-$14.03M$450.4K$19.74M$5.90M$1.88M$5.94M$2.29M
Share repurchases--$1.36M$14.21M------
Stock-based compensation$2.25M$5.43M$8.34M$7.54M$5.51M$2.74M$1.09M$1.33M$2.03M$69.6K
Depreciation and amortization$1.11M$1.38M$1.23M$1.28M$335.4K$138.6K$65.9K$50.8K$45.8K$37.5K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-84.1%-42.5%-80.1%-65.0%31.3%34579.9%438.6%420.9%--
Net income growth, YoY-----13.7%-----
EPS growth, YoY-----19.1%-----
Gross margin64.3%74.5%38.6%84.0%88.2%77.7%47.7%76.5%96.1%-
Operating margin-8058.8%-1023.7%-626.9%-78.8%47.1%55.9%-2741.6%-15328.6%-59567.6%-
Net margin-7533.6%-961.4%-518.7%-41.6%37.5%57.0%-2882.0%-15714.3%-90827.9%-
Free cash flow margin-4793.2%-763.8%-344.2%15.0%41.3%36.7%-2622.8%-10326.4%-43601.0%-
Return on equity-227.3%-69.9%-41.3%-12.4%27.3%63.7%-356.6%--180.7%-
Return on assets-189.5%-59.2%-37.1%-11.6%22.9%59.6%-279.7%-403.8%-149.3%-148.8%
Current ratio3.874.4110.8123.949.1416.694.830.457.090.31
Debt to equity--------0.07-

Source: XBRL data Co-Diagnostics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-30, first reported Mar 31, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CODX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CODX$721.4K-28.1%-$47.06M-6523.0%$2.3M
SYK$26.30B+7.9%$3.62B13.8%$124.05B
MMM$25.25B+1.7%$3.54B14.0%$95.67B
BSX$21.07B+8.9%$3.50B16.6%$61.96B
BDX$23.25B+17.4%$941.00M4.0%$57.71B
MDLN$30.68B-$683.00M2.2%$52.13B
RMD$5.73B+9.0%$1.59B27.8%$33.10B
DXCM$5.10B+13.0%$991.00M19.4%$29.62B
WST$3.40B+12.6%$638.90M18.8%$27.85B

CODX FAQ

8 questions
  • What is CODX revenue?
    Co-Diagnostics Inc. (CODX) reported $721.4K of revenue for the twelve months ended Jun 30, 2026. That is down 28.1% from the year before. Revenue for fiscal 2025 was $622.5K.
  • Is CODX profitable?
    No. Co-Diagnostics Inc. reported a net loss of $47.06M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does CODX have?
    Co-Diagnostics Inc. reported $3.65M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is CODX revenue growing?
    Co-Diagnostics Inc.'s revenue changed -84.1% in fiscal 2025, to $622.5K. Its compound annual growth rate was -61.6% over 5 years.
  • What is CODX gross margin?
    Co-Diagnostics Inc.'s gross profit was $313.6K on $721.4K of revenue for the twelve months ended Jun 30, 2026, a gross margin of 43.5%.
  • What is CODX free cash flow?
    Co-Diagnostics Inc. generated -$27.47M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$27.10M less capital expenditures.
  • When did CODX last report financial results?
    The latest statements here come from Co-Diagnostics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this CODX financial data come from?
    Quantisnow builds these statements from the structured XBRL data Co-Diagnostics Inc. files with the SEC. It is provided for information only and is not investment advice.